Teva announced the launch of Imatinib Mesylate Tablets, the generic version of Novartis‘ Gleevec

Gleevec is indicated for the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase; Ph+ CML in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy; Ph+ acute lymphoblastic leukemia (Ph+ ALL); myelodysplastic/myeloproliferative diseases associated with PDGFR gene re-arrangements; systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown; hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFR alpha fusion kinase and for patients with HES and/or CEL who are FIP1L1-PDGFR alpha fusion kinase negative or unknown; unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans; and as adjuvant treatment following resection of Kit positive GI stromal tumors (GIST). 

Related Articles

Imatinib Mesylate is a protein tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase. It inhibits proliferation and induces apoptosis in BCR-ABL positive cell lines as well as fresh leukemic cells. It also induces apoptosis in GIST cells, which express an activating c-kit mutation.

Imatinib Mesylate is available as 100mg strength tablets in 90-count bottles, and as 400mg strength tablets in 30-count bottles. 

For more information call (888) 838-2872 or visit